Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - fluconazole - solution for infusion - 2 mg/ml - fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - ranitidine hydrochloride - solution for inj/inf - 25 base mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - ranitidine hydrochloride - solution for inj/inf - 25 base mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - ondansetron hydrochloride dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - metronidazole -

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - bupivacaine hydrochloride - solution for injection - 2.5 mg/ml - amides

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - bupivacaine hydrochloride - solution for injection - 5.0 mg/ml - amides

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - frusemide -

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - solution - excipient ingredients: meglumine; water for injections; tetraxetan - clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).